Itraconazolo Teva

Itraconazole, the active ingredient in Itraconazolo Teva, is an azole antifungal presented as an oral formulation for systemic administration. It is used to treat a broad spectrum of fungal infections, ranging from superficial skin and nail conditions to serious invasive diseases, in adult patients.

GNH USA supplies Itraconazolo Teva as a licensed, GDP‑compliant international pharmaceutical supplier, providing the product to hospitals, pharmacies and clinics across global markets while adhering to stringent quality and regulatory standards.

Itraconazole is employed to manage fungal infections affecting the skin, nails, and internal organs.

- Dermatophytosis: eradicates dermatophyte organisms, leading to resolution of ringworm and related skin lesions. - Onychomycosis: penetrates the nail plate to eliminate fungal growth, improving nail appearance and health. - Candidiasis: treats mucosal and systemic Candida infections, reducing symptoms and preventing dissemination. - Aspergillosis: inhibits Aspergillus species, aiding recovery in invasive pulmonary disease. - Blastomycosis: clears Blastomyces dermatitidis infection in pulmonary and disseminated forms. - Histoplasmosis: combats Histoplasma capsulatum, supporting resolution of acute and chronic disease.

Itraconazole may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Nausea: mild to moderate stomach upset occurring after oral intake. - Headache: transient cranial discomfort reported by some patients. - Rash: skin irritation or mild erythema developing during therapy.

Serious or Rare Side Effects: - Hepatotoxicity: elevated liver enzymes or severe liver injury requiring monitoring. - Congestive heart failure: fluid retention and worsening of pre‑existing cardiac conditions. - Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis, demanding immediate discontinuation.

When prescribing itraconazole, clinicians should observe several safety considerations to minimize risk.

- Liver monitoring: Perform baseline and periodic liver function tests because hepatotoxicity can occur. - Cardiac assessment: Avoid use in patients with existing congestive heart failure due to risk of worsening symptoms. - Pregnancy caution: Use only if potential benefit justifies potential risk, as safety data are limited. - Drug interaction review: Evaluate concomitant medications that affect CYP3A4 metabolism. - Allergy check: Discontinue if hypersensitivity reactions such as rash or angioedema develop. - Store at room temperature: Keep in original container, protect from moisture and heat.

Itraconazole interacts with several medicines through CYP3A4 modulation and other mechanisms.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, ritonavir, clarithromycin): can raise itraconazole levels and increase toxicity. - Simvastatin and other CYP3A4‑metabolized statins: risk of severe myopathy. - Ergot alkaloids (e.g., ergotamine): may cause vasospasm and ischemia. - Quinidine and similar antiarrhythmics: can lead to arrhythmias. - Oral contraceptives: may reduce efficacy, leading to unintended pregnancy.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampin, carbamazepine): may lower itraconazole concentrations and reduce effectiveness. - Warfarin: itraconazole can increase INR, requiring closer monitoring. - Digoxin: possible increase in serum levels, monitor for toxicity. - Antihistamines (e.g., diphenhydramine): may enhance central nervous system effects. - HIV protease inhibitors (e.g., indinavir): may require dose adjustment.